Abeona Therapeutics (ABEO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 Jun, 2026Opening remarks and agenda
Meeting opened with acknowledgment of Michael Amoroso's resignation from the board for personal reasons, not related to company matters.
Michael Amoroso's name withdrawn from board election; no replacement nominated.
Principal agenda items included director elections, executive compensation, auditor ratification, equity plan amendment, and certificate of incorporation amendment.
Board and executive committee updates
Michael Amoroso thanked for years of service; his resignation effective prior to the meeting.
No replacement director nominated for election at this meeting.
Shareholder proposals
Election of two Class I Directors for three-year terms.
Advisory approval of executive compensation.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Approval sought to increase shares reserved under the 2023 Equity Incentive Plan from $8.4M to $11.5M.
Proposal to amend certificate of incorporation to remove advance notice provision for director nominations.
Latest events from Abeona Therapeutics
- A 12.49 million-share resale shelf follows the ABO-801 acquisition and $30 million private placement.ABEO
Registration filing - ZEVASKYN launch ramp leads, with ABO-801 and partnered-program catalysts ahead.ABEO
Jefferies Global Healthcare Conference - ABO-801 adds a redesigned EoE Phase III program alongside ZEVASKYN’s expanding launch.ABEO
Stifel 2026 Healthcare Conference 2026 - Strong histologic results; exploratory DSQ mapping informs symptom endpoint strategy.ABEO
Clinical Development History presentation - ZEVASKYN’s $11.4M Q2 revenue anchors a broader cell- and gene-therapy pipeline.ABEO
Corporate presentation - ZEVASKYN revenue rose 18% QoQ as ABO-801 advanced toward Phase III.ABEO
Q3 2026 - ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Durable gene therapy launch advances with expanding treatment centers and strong patient access.ABEO
Morgan Stanley 24th Annual Global Healthcare Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026